DNA Electronics CEO Prof. Chris Toumazou to address Scripps conference

LONDON, UK: DNA Electronics Ltd, a fabless provider of semiconductor solutions for real-time DNA and RNA detection, announced that chairman and CEO, Prof. Chris Toumazou, FRS, will be an invited speaker at the upcoming “The Future of Genomic Medicine IV” conference presented by the Scripps Translational Science Institute (March 1-2 2012, La Jolla, California).

Prof. Toumazou will be speaking as part of the “Hot Topics in Genomic Medicine” track, addressing a key presentation on “DNA Transistors and Handheld Sequencing” to the conference audience of physicians, healthcare professionals, human geneticists, genomic scientists and researchers. Prof. Toumazou’s presentation will explore how scalable semiconductor solutions for real-time nucleic acid detection can enable faster, simpler and more cost-effective DNA analysis platforms.

DNA Electronics – a spin-out of Imperial College London – was founded by semiconductor healthcare pioneer Prof. Toumazou, the inventor of the company’s core technology that allows CMOS transistors to be switched on and off with DNA. Prof. Toumazou’s innovation has culminated in the world’s first DNA logic on standard CMOS technology.

DNA Electronics has worldwide licensing agreements with Roche and semiconductor sequencing company Ion Torrent, providing non-exclusive access to DNA Electronics’ proprietary semiconductor technology portfolio, which enables sensitive detection of nucleotide incorporation during sequencing.

The fifth Future of Genomic Medicine conference will focus on the extraordinary advances that are occurring in the field, which include whole genome and exome sequencing, pharmacogenomics, and advances in cancer treatment as an outgrowth of genomics. The 2012 conference features a two-day curriculum from a renowned faculty representing the country’s leading institutions, headed by Director of Scripps Translational Science Institute Eric Topol M.D.

Part of San Diego, California-based Scripps Health, the Scripps Translational Science Institute (STSI) is a unique community collaboration that initiates research that moves basic science from the lab to the patient bedside. STSI is supported by the NIH flagship program, Clinical and Translational Science Award (CTSA).

Collaborators in the STSI consortium include Scripps Health; The Scripps Research Institute; the Burnham Institute for Medical Research; Children’s Hospital of Philadelphia; Genomics Institute of the Novartis Research Foundation; The J. Craig Venter Institute; Salk Institute for Biological Studies; San Diego State University; San Diego Supercomputer Center; and The Neurosciences Institute.